pharma · Carcinoma, Renal Cell · Human Immunodeficiency Virus (HIV) Infection
Merck KGaA, Darmstadt
Merck KGaA, Darmstadt, Germany
Merck KGaA, Darmstadt is a pharma organization headquartered in Darmstadt, DE. Primary therapeutic focus areas include Carcinoma, Renal Cell, Human Immunodeficiency Virus (HIV) Infection, Systemic Lupus Erythematosus, So
Frankfurter Str. 250, Darmstadt, 64293, DE HQ
7,364 Employees
NMPA registrant Type
Company details
- Status
- Public
- HQ
- Frankfurter Str. 250, Darmstadt, 64293, DE
- Employees
- 7,364
- Programs
- 63
- Drugs
- 50
- Patents
- 0
Efinopegdutide 20 mg/mL
Phase 2 · small molecule · Nonalcoholic Fatty Liver Disease
Efinopegdutide 20 mg/mL for Nonalcoholic Fatty Liver Disease is a Phase 2 program (small_molecule) at Merck KGaA, Darmstadt, Germany with 1 ClinicalTrials.gov record(s).
Internal code 6024-001
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Merck KGaA, Darmstadt, Germany
- Phase
- Phase 2
- Modality
- small_molecule
- Indication
- Nonalcoholic Fatty Liver Disease
- Status
- completed
- Trials
- 1